Yuko Sakai-Tagawa
Overview
Explore the profile of Yuko Sakai-Tagawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
5789
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Furusawa Y, Kiso M, Uraki R, Sakai-Tagawa Y, Nagai H, Koga M, et al.
J Virol
. 2025 Feb;
:e0221724.
PMID: 39936915
Importance: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replicates efficiently at 37°C. However, the temperature of the human upper airway is 30°C-32°C. Therefore, the replicative ability of SARS-CoV-2 at low...
2.
Halfmann P, Iwatsuki-Horimoto K, Kuroda M, Hirata Y, Yamayoshi S, Iida S, et al.
Commun Biol
. 2024 Mar;
7(1):331.
PMID: 38491227
During the Omicron wave, previous variants such as BA.2, BA.4, and BA.5 were replaced by newer variants with additional mutations in the spike protein. These variants, BA.4.6, BQ.1.1, and XBB,...
3.
Hagihara M, Hayashi H, Nakashima S, Imai Y, Nakano H, Uchida T, et al.
Intern Med
. 2024 Jan;
63(16):2283-2287.
PMID: 38171874
Objective Prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been reported in immunocompromised patients, as they poorly develop antibodies against SARS-CoV-2. We conducted a clinical trial to determine...
4.
Uraki R, Kiso M, Iwatsuki-Horimoto K, Yamayoshi S, Ito M, Chiba S, et al.
Cell Rep
. 2023 Dec;
42(12):113580.
PMID: 38103202
EG.5.1 is a subvariant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron XBB variant that is rapidly increasing in prevalence worldwide. However, the pathogenicity, transmissibility, and immune evasion...
5.
Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Sakai-Tagawa Y, et al.
iScience
. 2023 Oct;
26(11):108147.
PMID: 37876803
The emergence and spread of new SARS-CoV-2 variants with mutations in the spike protein, such as the XBB.1.5 and XBB.1.9.1 sublineages, raise concerns about the efficacy of current COVID-19 vaccines...
6.
Yamamoto S, Yamayoshi S, Ito M, Sakai-Tagawa Y, Nakachi I, Baba R, et al.
iScience
. 2023 Jul;
26(7):107208.
PMID: 37448563
SARS-CoV-2 has gradually acquired amino acid substitutions in its S protein that reduce the potency of neutralizing antibodies, leading to decreased vaccine efficacy. Here, we attempted to obtain mutant viruses...
7.
Sakai-Tagawa Y, Yamayoshi S, Halfmann P, Wilson N, Bobholz M, Vuyk W, et al.
J Med Virol
. 2023 May;
95(5):e28788.
PMID: 37212288
Diagnosis by rapid antigen tests (RATs) is useful for early initiation of antiviral treatment. Because RATs are easy to use, they can be adapted for self-testing. Several kinds of RATs...
8.
Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Sakai-Tagawa Y, et al.
Lancet Reg Health West Pac
. 2023 May;
34:100777.
PMID: 37193320
No abstract available.
9.
Uraki R, Iida S, Halfmann P, Yamayoshi S, Hirata Y, Iwatsuki-Horimoto K, et al.
Nat Commun
. 2023 Mar;
14(1):1620.
PMID: 36959194
The prevalence of the Omicron subvariant BA.2.75 rapidly increased in India and Nepal during the summer of 2022, and spread globally. However, the virological features of BA.2.75 are largely unknown....
10.
Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Sakai-Tagawa Y, et al.
Lancet Infect Dis
. 2023 Mar;
23(5):525-526.
PMID: 36898405
No abstract available.